Our objective is to become a leader in the development of end stage blood cancer treatments by leveraging our development, clinical and regulatory experience to bring to the market innovative products that target significant unmet medical needs. Our strategy is to rapidly advance our lead blood cancer products in the European Union, the United States and Canada targeting orphan indications. We intend to strengthen our relationships with leading transplantation specialists and to retain independent marketing rights to drive direct sales of our blood cancer products to transplantation centers.